{"success":true,"data":{"pressRelease":{"id":"116891","rtpr_id":"nNFC9SJsZw","ticker":"NTHI","exchange":"NASDAQ","all_tickers":["NTHI"],"title":"NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x","author":"Newsfile Corp","published_at":"2026-08-12T13:25:18.495Z","article_body":"Phase 2a results showed 48.9% six-month progression-free survival versus a 20%\nhistorical benchmark, with median overall survival reaching approximately 26\nmonths\n\nHouston, Texas--(Newsfile Corp. - August 12, 2026) - NeOnc Technologies\nHoldings (NASDAQ: NTHI) reported encouraging Phase 2a results for intranasal\nNEO100 in patients with recurrent IDH1-mutant high-grade glioma, showing a\n48.9% six-month progression-free survival rate compared with a 20% historical\nbenchmark.\n\nThe result was nearly 2.5 times the historical benchmark and was statistically\nsignificant at p=0.0047.\n\nThe study enrolled patients with advanced recurrent Grade III or Grade IV\nglioma whose tumors had already returned or progressed following standard\nradiation and chemotherapy, a patient population with extremely limited\nremaining treatment options.\n\nSupporting survival data were also encouraging. Median overall survival\nreached approximately 26 months, with roughly 87% of patients alive at six\nmonths, 61% at one year and 54% at two years. Several patients remained on\ntreatment, including one who had remained progression-free for nearly 19\nmonths.\n\nNEO100 is administered intranasally four times daily and can be taken at home.\nThe study also reported no major toxicities.\n\nThe Phase 2a study enrolled 24 patients and was open-label, which is typical\nof early-to-mid-stage studies involving narrowly defined populations of\nseriously ill patients with recurrent disease who have exhausted standard\ntreatment options. Larger confirmatory trials would represent the normal next\nstep following a successful Phase 2 signal.\n\nNeOnc plans to meet with the FDA to discuss the path toward a larger\nregistrational study that could potentially support future approval.\n\nThe positive Phase 2a results also arrive alongside recent research upgrades\nand a substantial short position, creating additional market attention as\ninvestors begin evaluating the significance of the NEO100 data.\n\nFor NeOnc, the headline is straightforward: NEO100 substantially exceeded its\nhistorical Phase 2a benchmark, delivered statistically significant results,\nand now advances toward its next regulatory step.\n\nAbout Wall Street PR\n\nWall Street PR (WSTPR) is your premier destination for intelligent investor\nrelations and financial communications. We deliver meticulously curated market\nintelligence, breaking news alerts, exclusive expert insights, and in-depth\nanalysis to help investors and traders stay ahead in today's fast-moving\nmarkets. Whether you're a seasoned professional or an emerging investor, our\nplatform provides hard-to-find information on earnings reports, regulatory\nshifts, market trends, and emerging opportunities, empowering you to make\nconfident, well-informed decisions.\n\nFor companies, we specialize in high-impact Investor and Public Relations. We\ntransform significant corporate milestones into compelling stories that\nresonate with investors, analysts, and the media. Our experienced team crafts\nstrategic press releases and communications that cut through the noise,\nensuring your achievements reach major outlets such as Forbes, Barron's,\nInvestor's Business Daily, The Wall Street Journal, and beyond. With superior\nreach across more than 7,500 media outlets and strong relationships with\ninfluential financial newsletter writers, we maximize visibility and deliver\nyour message clearly, whether celebrating success or navigating challenges.\n\nThrough targeted distribution, email newsletters, and strategic storytelling,\nWall Street PR helps public companies build credibility, engage shareholders,\nand enhance market presence with precision and professionalism.\n\nFor further information, please go to https://wallstreet-pr.com/.\n\nPAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for\ninformational purposes only. WSTPR is a third-party media provider that has\nbeen compensated $1,500 for this editorial by 247 MN on behalf of the company\nfor providing ongoing NTHI editorial market outreach and other services. This\npress release may include technical analysis and should not be construed as\nfinancial or investment advice. Trading stocks involves risks, and readers\nshould consult with their financial advisor before making investment\ndecisions. For further info https://wallstreet-pr.com/disclosure-nhti/.\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements that are subject to\nvarious risks and uncertainties. Such statements include statements regarding\nthe Company's ability to grow its business and other statements that are not\nhistorical facts, including statements which may be accompanied by the words\n\"intends,\" \"may,\" \"will,\" \"plans,\" \"expects,\" \"anticipates,\" \"projects,\"\n\"predicts,\" \"estimates,\" \"aims,\" \"believes,\" \"hopes,\" \"potential\" or similar\nwords. Actual results could differ materially from those described in these\nforward-looking statements due to a number of factors, including without\nlimitation, the Company's ability to continue as a going concern, general\neconomic conditions, and other risk factors detailed in the Company's filings\nwith the SEC. The forward-looking statements contained in this press release\nare made as of the date of this press release, and the Company does not\nundertake any responsibility to update such forward-looking statements except\nin accordance with applicable law.\n\nCONTACT:\nWall Street PR\neditor@wallstreet-pr.com\n\n(https://images.newsfilecorp.com/files/12294/309320_neonc-technologies-holding-logo-vector_200.jpg)\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/309320","article_body_html":"","raw_payload":{"data":{"id":"nNFC9SJsZw","title":"NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x","author":"Newsfile Corp","ticker":"NTHI","created":"2026-08-12T13:25:18.495Z","tickers":["NTHI"],"exchange":"NASDAQ","article_body":"Phase 2a results showed 48.9% six-month progression-free survival versus a 20%\nhistorical benchmark, with median overall survival reaching approximately 26\nmonths\n\nHouston, Texas--(Newsfile Corp. - August 12, 2026) - NeOnc Technologies\nHoldings (NASDAQ: NTHI) reported encouraging Phase 2a results for intranasal\nNEO100 in patients with recurrent IDH1-mutant high-grade glioma, showing a\n48.9% six-month progression-free survival rate compared with a 20% historical\nbenchmark.\n\nThe result was nearly 2.5 times the historical benchmark and was statistically\nsignificant at p=0.0047.\n\nThe study enrolled patients with advanced recurrent Grade III or Grade IV\nglioma whose tumors had already returned or progressed following standard\nradiation and chemotherapy, a patient population with extremely limited\nremaining treatment options.\n\nSupporting survival data were also encouraging. Median overall survival\nreached approximately 26 months, with roughly 87% of patients alive at six\nmonths, 61% at one year and 54% at two years. Several patients remained on\ntreatment, including one who had remained progression-free for nearly 19\nmonths.\n\nNEO100 is administered intranasally four times daily and can be taken at home.\nThe study also reported no major toxicities.\n\nThe Phase 2a study enrolled 24 patients and was open-label, which is typical\nof early-to-mid-stage studies involving narrowly defined populations of\nseriously ill patients with recurrent disease who have exhausted standard\ntreatment options. Larger confirmatory trials would represent the normal next\nstep following a successful Phase 2 signal.\n\nNeOnc plans to meet with the FDA to discuss the path toward a larger\nregistrational study that could potentially support future approval.\n\nThe positive Phase 2a results also arrive alongside recent research upgrades\nand a substantial short position, creating additional market attention as\ninvestors begin evaluating the significance of the NEO100 data.\n\nFor NeOnc, the headline is straightforward: NEO100 substantially exceeded its\nhistorical Phase 2a benchmark, delivered statistically significant results,\nand now advances toward its next regulatory step.\n\nAbout Wall Street PR\n\nWall Street PR (WSTPR) is your premier destination for intelligent investor\nrelations and financial communications. We deliver meticulously curated market\nintelligence, breaking news alerts, exclusive expert insights, and in-depth\nanalysis to help investors and traders stay ahead in today's fast-moving\nmarkets. Whether you're a seasoned professional or an emerging investor, our\nplatform provides hard-to-find information on earnings reports, regulatory\nshifts, market trends, and emerging opportunities, empowering you to make\nconfident, well-informed decisions.\n\nFor companies, we specialize in high-impact Investor and Public Relations. We\ntransform significant corporate milestones into compelling stories that\nresonate with investors, analysts, and the media. Our experienced team crafts\nstrategic press releases and communications that cut through the noise,\nensuring your achievements reach major outlets such as Forbes, Barron's,\nInvestor's Business Daily, The Wall Street Journal, and beyond. With superior\nreach across more than 7,500 media outlets and strong relationships with\ninfluential financial newsletter writers, we maximize visibility and deliver\nyour message clearly, whether celebrating success or navigating challenges.\n\nThrough targeted distribution, email newsletters, and strategic storytelling,\nWall Street PR helps public companies build credibility, engage shareholders,\nand enhance market presence with precision and professionalism.\n\nFor further information, please go to https://wallstreet-pr.com/.\n\nPAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for\ninformational purposes only. WSTPR is a third-party media provider that has\nbeen compensated $1,500 for this editorial by 247 MN on behalf of the company\nfor providing ongoing NTHI editorial market outreach and other services. This\npress release may include technical analysis and should not be construed as\nfinancial or investment advice. Trading stocks involves risks, and readers\nshould consult with their financial advisor before making investment\ndecisions. For further info https://wallstreet-pr.com/disclosure-nhti/.\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements that are subject to\nvarious risks and uncertainties. Such statements include statements regarding\nthe Company's ability to grow its business and other statements that are not\nhistorical facts, including statements which may be accompanied by the words\n\"intends,\" \"may,\" \"will,\" \"plans,\" \"expects,\" \"anticipates,\" \"projects,\"\n\"predicts,\" \"estimates,\" \"aims,\" \"believes,\" \"hopes,\" \"potential\" or similar\nwords. Actual results could differ materially from those described in these\nforward-looking statements due to a number of factors, including without\nlimitation, the Company's ability to continue as a going concern, general\neconomic conditions, and other risk factors detailed in the Company's filings\nwith the SEC. The forward-looking statements contained in this press release\nare made as of the date of this press release, and the Company does not\nundertake any responsibility to update such forward-looking statements except\nin accordance with applicable law.\n\nCONTACT:\nWall Street PR\neditor@wallstreet-pr.com\n\n(https://images.newsfilecorp.com/files/12294/309320_neonc-technologies-holding-logo-vector_200.jpg)\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/309320"},"type":"article","timestamp":"2026-08-12T13:25:18.579260054Z","server_sent_at_ms":1786541118579},"received_at":"2026-08-12T13:25:18.630Z","source_url":"https://www.newsfilecorp.com/release/309320"},"analysis":{"id":"105881","press_release_id":"116891","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Press release is a paid editorial communication ($1,500 compensated by 247 MN)","Study consisted of only 24 patients and was open-label"],"eventType":"clinical_trial","narrative":"Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma showed 48.9% six-month progression-free survival, nearly 2.5x the 20% historical benchmark (p=0.0047).\n\nMedian overall survival reached approximately 26 months with no major toxicities reported in the 24-patient open-label study.\n\nNeOnc plans to meet with the FDA to discuss a path toward a larger registrational study following these positive signals.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Phase 2a data showed 2.5x improvement in PFS vs benchmark; FDA meeting planned."},"keyFigures":{"drugName":"NEO100","phaseOfTrial":"Phase 2a","customDimensions":{"p_value":"0.0047","patients_enrolled":24,"six_month_pfs_rate":"48.9%","historical_benchmark_pfs":"20%","median_overall_survival_months":"approx 26"}},"quotedText":"The result was nearly 2.5 times the historical benchmark and was statistically significant at p=0.0047.","namedEntities":{"people":[],"products":["NEO100"],"companies":[{"name":"NeOnc Technologies Holdings","ticker":"NTHI"},{"name":"Wall Street PR","relationship":"media provider"},{"name":"247 MN","relationship":"compensating party"}],"dollarAmounts":[{"amount":"$1,500","context":"paid editorial compensation"}]},"materialImpact":{"score":4,"reasoning":"Phase 2a data demonstrated statistically significant superiority over historical benchmarks (48.9% vs 20% PFS) with no major toxicities, positioning the company for FDA discussions on a registrational study."},"tickerRelevance":{"others":[],"primary":"NTHI"},"globalImportance":25,"audienceRelevance":35,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"phase-2-data","retailAttention":"short-squeeze-mention"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":4,"narrative":"Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma showed 48.9% six-month progression-free survival, nearly 2.5x the 20% historical benchmark (p=0.0047).\n\nMedian overall survival reached approximately 26 months with no major toxicities reported in the 24-patient open-label study.\n\nNeOnc plans to meet with the FDA to discuss a path toward a larger registrational study following these positive signals.","key_figures":{"drugName":"NEO100","phaseOfTrial":"Phase 2a","customDimensions":{"p_value":"0.0047","patients_enrolled":24,"six_month_pfs_rate":"48.9%","historical_benchmark_pfs":"20%","median_overall_survival_months":"approx 26"}},"named_entities":{"people":[],"products":["NEO100"],"companies":[{"name":"NeOnc Technologies Holdings","ticker":"NTHI"},{"name":"Wall Street PR","relationship":"media provider"},{"name":"247 MN","relationship":"compensating party"}],"dollarAmounts":[{"amount":"$1,500","context":"paid editorial compensation"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-12T17:12:33.377Z","global_importance":25,"audience_relevance":35,"importance_components":{"tickerTier":"small-cap","eventGravity":"phase-2-data","retailAttention":"short-squeeze-mention"}},"durationMs":null,"modelName":"glm-4.7"}}